Our research
Our research group is dedicated to pioneering nanomedicines tailored for combating cancer, particularly glioblastoma, by innovating engineered polymeric and lipidic nanomaterials. We focus on overcoming critical barriers such as the blood-brain barrier to enable non-viral gene delivery and controlled release of biologics.
Our vision extends beyond the lab, aiming for translational impact through clinical trials, anticipating a future where our advancements revolutionize treatment protocols, significantly enhance patient survival rates, and improve the quality of life for individuals battling this devastating disease.
Our vision
01
Biologics delivery
We have been working on the delivery of monoclonal antibodies, proteins and peptides through polymeric nanoparticles for the treatment of Glioblastoma via intranasal and intravenous administration.
02
Cancer Immunotherapies
We are currently working on the development of cancer nanovaccines loaded with saRNA encoding pro-inflammatory cytokines.
